00:57 , Jan 6, 2017 |  BC Extra  |  Company News

J&J reveals spate of partnerships

The Johnson & Johnson Innovation unit of Johnson & Johnson (NYSE:JNJ) unveiled a series of new partnerships Thursday, including collaborations in cancer, immunotherapy, and non-alcoholic steatohepatitis (NASH). Among the 15 deals, J&J's Janssen Pharmaceuticals unit...
08:00 , Feb 28, 2011 |  BC Week In Review  |  Clinical News

BPX-101: Additional Phase I/II data

Additional data from an open-label, dose-escalation, U.S. Phase I/II trial in 12 patients showed that low-, mid- and high-doses of intradermal BPX-101 given every other week in combination with AP1903 for 6 doses produced a...
07:00 , Apr 26, 2010 |  BC Week In Review  |  Clinical News

BPX-101: Interim Phase I/II data

Interim data from a Phase I/II trial in 6 evaluable patients showed that low- and mid-doses of intradermal BPX-101 given every other week in combination with AP1903 for 6 doses produced 4 cases of stable...
07:00 , Oct 15, 2009 |  BC Innovations  |  Distillery Techniques

Technology: Disease models

Disease models CD1-expressing transgenic mouse models of Mycobacterium tuberculosis infection Mice engineered to express human CD1 molecules could serve as a model of tuberculosis to help guide development of TB vaccines. In M. tuberculosis-infected patients,...
07:00 , Aug 10, 2009 |  BC Week In Review  |  Clinical News

BP-GMAX-CD1: Phase I/IIa started

Bellicum began an open-label, dose-escalation, U.S. Phase I/IIa trial in 24 patients to evaluate 6 doses of intradermal BP-GMAX-CD1 given weekly or every other week in combination with activating agent AP1903. Ariad granted Bellicum a...
07:00 , Aug 7, 2008 |  BC Innovations  |  Distillery Therapeutics

This Week in Therapeutics

This week in therapeutics Indication Target/marker/ pathway Summary Licensing status Publication and contact information Infectious Disease Tuberculosis Group I CD1 isoforms (CD1a, CD1b and CD1c) A study in cell culture suggests that lipid antigens that...
07:00 , Aug 7, 2008 |  BC Innovations  |  Targets & Mechanisms

Avoiding TB's subversion

Mycobacterium tuberculosis has proven a tough bug to tame, with no effective vaccines on the market to stop the bacterium's spread. Now, a study published in the Proceedings of the National Academy of Sciences describes...
07:00 , Mar 27, 2008 |  BC Innovations  |  Cover Story

Antigens by Special Delivery

DNA vaccines often require high and repeated dosing of antigen, which suggests suboptimal priming of the immune system and results in weak immunogenicity. 1 Separate papers in Nature Biotechnology and the Journal of Clinical Investigation...
07:00 , Oct 16, 2006 |  BC Week In Review  |  Company News

Ariad, Bellicum deal

ARIA granted Bellicum a non-exclusive license to Argent cell signaling regulation technology, including the dimerizing compound AP1903 , for use in cancer vaccines. ARIA will get an undisclosed equity stake in Bellicum and will be...
07:00 , Sep 11, 2000 |  BC Week In Review  |  Company News

Aquila other research news

AQLA received a $127,989 Phase I SBIR grant from the National Institute of Allergy and Infectious Diseases to develop vaccines to prevent S. aureus infections using AQLA's CD1 antigen presentation immune enhancement technology. Aquila Biopharmaceuticals...